Watson Pharmaceuticals, Inc. May Pay $6 Billion Actavis

Watson Pharmaceuticals Inc. (WPI) might announce a deal to buy Actavis for around $6 billion on Wednesday, the Reuters news agency said Monday on its website, citing unnamed sources familiar with the matter. The deal, first reported in March, is likely to be valued at EUR 4.25 billion ($5.6 billion), less than the expected EUR 5-5.5 billion, the report said, citing a source.

Back to news